Decipher genomic score guides abiraterone intensification in prostate cancer
Start here
A University College London team presented a new analysis of the STAMPEDE trial at a cancer conference in Madrid, showing the Decipher genomic test can stratify prostate cancer patients by risk. Each 0.1 increase in Decipher score corresponded to a hazard ratio of 1.49 for distant metastasis and 1.38 for prostate cancer death. Real-world data from 27,607 cases and 401 cases from the randomized trial consistently showed that high-score patients benefited from abiraterone intensification, while low-score patients might be spared overtreatment. The UK NHS has already rolled out abiraterone for high-risk locally advanced prostate cancer. Broader adoption of the test to guide treatment decisions is still under discussion.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- medicalxpress.comPickDiagnostic test could help doctors refine prostate cancer treatment
A University College London team presented a new analysis of the STAMPEDE trial at a cancer conference in Madrid: each 0.1 increase in the Decipher genomic test score carried a hazard ratio of 1.49 for distant metastasis and 1.38 for prostate cancer death. Real-world data on 27,607 cases and randomized trial data on 401 patients consistently showed that high-score patients benefit from intensified abiraterone treatment, while low-score patients may avoid overtreatment. The UK NHS has already rolled out abiraterone for high-risk locally advanced prostate cancer.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 05:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.